Workflow
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
EBSEmergent BioSolutions(EBS) Newsfilter·2025-03-03 21:23

Core Insights - Emergent BioSolutions Inc. reported favorable full-year financial results for 2024, driven by core products and strategic stabilization actions [2][6][37] - The company aims to focus on profitable revenue growth and cash generation as part of its multi-year transformation plan [2][6] Financial Highlights - Q4 2024 total revenues were 194.7million,adecreaseof30194.7 million, a decrease of 30% compared to Q4 2023 [3][6] - Q4 2024 net loss was 31.3 million, a 37% improvement from a net loss of 49.5millioninQ42023[3][6]−AdjustedEBITDAforQ42024was49.5 million in Q4 2023 [3][6] - Adjusted EBITDA for Q4 2024 was 21.0 million, an increase of 518% from 3.4millioninQ42023[3][6]−Full−year2024totalrevenueswere3.4 million in Q4 2023 [3][6] - Full-year 2024 total revenues were 1.04 billion, a slight decrease of 1% from 1.05billionin2023[4][6]SegmentPerformance−CommercialProductssegmentrevenuesdecreasedby201.05 billion in 2023 [4][6] Segment Performance - Commercial Products segment revenues decreased by 20% year-over-year to 398.9 million in 2024 [31][32] - MCM Products segment revenues increased by 14% year-over-year to 509.8millionin2024[33][35]−Servicessegmentrevenuesincreasedby34509.8 million in 2024 [33][35] - Services segment revenues increased by 34% year-over-year to 104.9 million in 2024 [36] Product Sales Breakdown - Q4 2024 product sales for NARCAN® decreased by 41% to 65.1millioncomparedtoQ42023[9][10]−RevenuesfromAnthraxMCMproductsdecreasedby7165.1 million compared to Q4 2023 [9][10] - Revenues from Anthrax MCM products decreased by 71% to 32.5 million in Q4 2024 [11] - Smallpox MCM revenues increased significantly by 565% to 76.5millioninQ42024[12]OperatingExpenses−TotaloperatingexpensesforQ42024decreasedby3676.5 million in Q4 2024 [12] Operating Expenses - Total operating expenses for Q4 2024 decreased by 36% to 204.2 million compared to Q4 2023 [17] - Research and development expenses decreased by 69% to 9.1millioninQ42024[20]−Selling,generalandadministrativeexpensesdecreasedby329.1 million in Q4 2024 [20] - Selling, general and administrative expenses decreased by 32% to 60.8 million in Q4 2024 [20] Future Guidance - The company forecasts total revenues for 2025 to be between 750millionand750 million and 850 million [38] - Adjusted EBITDA for 2025 is expected to be between 150millionand150 million and 200 million [38]